Evidence map›Paper›PMID 42199345›Full record

ReviewFrontiers in cell and developmental biology2026

Epigenetic dysregulation in mycosis fungoides and sézary syndrome.

Vinícius de Camargo Callefi, Isadora Alves, Nélio Cézar De Aquino, Sofia Cattena, Emanuelle Santos, Ketelyn Vasconcelos, Hebert Fabricio Culler, Luís Alberto de Pádua Covas Lage, Vanderson Rocha, Adriana Castello Costa Girardi and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Vinícius de Camargo CallefiReal-World Evidence Observatory and Lab for Precision Public Health, Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of São Paulo (FM-USP), São Paulo, Brazil.
Isadora AlvesReal-World Evidence Observatory and Lab for Precision Public Health, Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of São Paulo (FM-USP), São Paulo, Brazil.
Nélio Cézar De AquinoReal-World Evidence Observatory and Lab for Precision Public Health, Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of São Paulo (FM-USP), São Paulo, Brazil.
Sofia CattenaReal-World Evidence Observatory and Lab for Precision Public Health, Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of São Paulo (FM-USP), São Paulo, Brazil.
Emanuelle SantosReal-World Evidence Observatory and Lab for Precision Public Health, Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of São Paulo (FM-USP), São Paulo, Brazil.
Ketelyn VasconcelosReal-World Evidence Observatory and Lab for Precision Public Health, Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of São Paulo (FM-USP), São Paulo, Brazil.
Hebert Fabricio CullerLaboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of São Paulo (FM-USP), São Paulo, Brazil.
Luís Alberto de Pádua Covas LageLaboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of São Paulo (FM-USP), São Paulo, Brazil.
Vanderson RochaLaboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of São Paulo (FM-USP), São Paulo, Brazil.
Adriana Castello Costa GirardiLaboratory of Renal Physiology and Cardiometabolism, Department of Cardiopneumology, University of São Paulo (FMUSP), São Paulo, Brazil.
José Antonio SanchesDepartment of Dermatology, University of São Paulo Medical School, São Paulo, Brazil.
Carlos Alejandro Murga-ZamalloaDepartment of Pathology, University of Illinois at Chicago, Chicago, IL, United States.
Juliana PereiraLaboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of São Paulo (FM-USP), São Paulo, Brazil.
Cadiele Oliana ReichertReal-World Evidence Observatory and Lab for Precision Public Health, Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of São Paulo (FM-USP), São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cutaneous T-cell lymphomas (CTCL), including mycosis fungoides (MF) and Sézary syndrome (SS), remain challenging to diagnose at early stages and to manage durably. Although staging and classification have improved, early MF can mimic benign inflammatory dermatoses, and advanced disease frequently develops resistance to standard therapies, including histone deacetylase (HDAC) inhibitors. Here, we summarize how aberrant DNA methylation and histone modifications contribute to CTCL pathogenesis, promote a permissive tumor microenvironment, and enable immune escape, as well as emerging epigenetic biomarkers, such as microRNA signatures and promoter hypermethylation, that may improve diagnostic accuracy and patient stratification. Finally, we discuss resistance mechanisms linked to epigenetic plasticity and intratumoral heterogeneity and highlight future strategies combining rational drug regimens with longitudinal single-cell profiling to improve the durability of response.

Indexed as

cutaneous T-cell lymphoma (CTCL)DNA methylationepigeneticsHDAC inhibitorshistone acetylationmicroRNAprecision medicinetherapeutic resistance

Identifiers

PMID42199345
PMCPMC13199248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.